drugset / Trial / NCT06678607
Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Phase I clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Shanghai Reinovax Biologics Co., LTD will be conducted in Chinese adults aged 18 years and older . The objective of the study is to evaluate the safety and tolerability of PCV24. The trial is a single-center, randomized, blind,parallel-controlled design I clinical trial.
Timeline
- Start
- 2023-11-19
- Primary completion
- 2024-07-28
- Completion
- 2024-07-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Reinovax PCV24 formulation 1 | Vaccine | 0.5 ml | Intramuscular |
| Subject | Reinovax PCV24 formulation 2 | Vaccine | 0.5 ml | Intramuscular |